A human plasma protein could make producing pluripotent stem cells cheaper and faster according to academics in the UK and Sweden and partner GE Healthcare.
Researchers supported by the National Institutes of Health (NIH) have developed a clinical-grade stem cell line, which will help accelerate early-stage clinical research.
India’s first off-the-shelf cell therapy product, StemCells Inc plummets on Phase II trial termination, and Accellta looks to 3D printing. Welcome to Biopharma-Reporter’s stem cell round-up…
BioLife Solutions has partnered with transportation firm MNX and says it expects increased demand for its biologistics services as more cell therapies enter the clinic.
Daiichi Sankyo has paid Cell Therapy Ltd £12.5m ($18m) for the Japanese rights to its cardiac regeneration candidate Heartcel, made from allogeneic stem cells.
While there are currently several techniques for producing tissue from heart cells, a new method reduces the amount of cells needed, making it easier and cheaper to replicate.
Eppendorf will tackle the challenges of scaling-up human induced pluripotent stem cells (hiPSCs) as part of a Horizon 2020 project to develop cell-based heart therapies.
Cell therapy firms must invest in engineering and learn from biopharma according to the US Government, which says high cost of regenerative treatments is slowing uptake.
Scaling-up without expanding its manufacturing footprint was key in selecting Pall's Xpansion bioreactor, says UCL which is looking to create “the world’s largest therapeutic cell bank.”
Cell Therapy Manufacturing & Gene Therapy Congress - Brussels, Belgium
The shelf life of a cell therapy product is crucial in determining a firm’s manufacturing strategy according to the makers of the first approved stem-cell based drug.
Regenerative medicine developers now have a new supplier for mesenchymal stem cells (MSCs), the multipotent stromal cells derived from marrow and other tissues like muscle and dental pulp for tissue repair.
Reneuron has been granted a US patent for a cryopreservation technology that does not rely on toxic reagents and says it would consider licensing it to other stem cell therapy developers on a case-by-case basis.
Biocision has revamped its cell thawing platform to accommodate larger vial sizes and started developing an automated system for cell therapies in cryopreservation bags.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
The $2.4bn market for “unproven” and “unethical” biologics market “preys on vulnerable patients” and harms development of legitimate large molecule drugs, says the International Society for Cellular Therapy (ISCT).
Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.
Oklahoma-based contract development and manufacturer Cytovance Biologics has teamed up with NeuroFx to develop and manufacture a stem cell derived, cell-free therapy for neurological conditions.
Mass produced regenerative therapies are a step closer say UK researchers who have developed a polymer substrate they claim can be used to set up “stem cell factories.”
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.
German-based contract manufacturer apceth has received regulatory approval to use two new GMP cleanrooms for aseptic processing, which will be used for the handling and genetic manipulation of various types of cell and gene therapies.
California-based Allele has bought a facility to manufacture human induced pluripotent stem cells (hiPSCs) using its “footprint-free” synthetic mRNA technology.
Fujifilm will buy Cellular Dynamics International (CDI) for $307m to add induced stem cells to its offering and further build in regenerative medicines.
Sourcing human beta cells may soon no longer be a challenge for AstraZeneca diabetes researchers thanks to a new partnership with stem cell scientists at Harvard University.
Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.
Australian stem cell and regenerative medicine company Cynata Therapeutics is now set to scale up manufacturing of its mesenchymal stem cells (MSCs) for therapeutic use.
In a reversal from three years ago, the Court of Justice of the European Union (CJEU) ruled on Thursday that an organism incapable of developing into a human being is not a human embryo and may be patented.
Analyst firm N+1Singer has endorsed stem cell manufacturer Reneuron based on its “off-the-shelf” therapy pipeline and a new facility that will reduce the need to outsource.
Regenerative medicine company Advanced Cell Technology (ACT) has been issued a US patent from the US Patent and Trademark Office covering methods of manufacturing dendritic cells using a scalable process involving a renewable stem cell source as the starting...
A German biobank has made stem cells available to active pharmaceutical ingredient (API) firms this week in a bid to support industry drug development efforts.
US FDA researchers are developing tools to help cell therapy developers improve how they manufacture stem cells in a new lab consortium unveiled by the agency this week.
Second quarter sales of cryopreservation media grew 14% but BioLife Solutions says it expects revenues to skyrocket as clients’ biologics move out of the clinical stage..
UK stem cell storage firm Precious Cells BioBank (PCB) has bought tech company Pharmacells Group in a deal it says will accelerate its growth in the biologics sector.
Lonza has launched a new stem cell reprogramming and maintenance system that has already been used to support US NIH and pharmaceutical company preclinical drug development projects.
A new cell therapy development centre has opened at Guy’s Hospital in London today in the latest stage of a Government-backed effort to establish the UK as a global hub.
